SNHG16 is overexpressed in a variety of cancers (Gong et al., 2020), such as neuroblastoma (Xu et al., 2020), lung cancer (Xia et al., 2021), thyroid cancer (Wen et al., 2019), and breast cancer (Du et al., 2020). Here, SNHG16 is linked to neuroblastoma.